(Q47685036)

4 February 2018

title

Low-dose methotrexate in the treatment of widespread morphea (English)

1 reference

4 February 2018

1 reference

Seyger MM

1

1 reference

4 February 2018

van den Hoogen FH

series ordinal

2

1 reference

4 February 2018

de Boo T

series ordinal

3

1 reference

4 February 2018

de Jong EM

series ordinal

4

1 reference

4 February 2018

language of work or name

English

0 references

publication date

1 August 1998

1 reference

4 February 2018

Journal of the American Academy of Dermatology

published in

1 reference

4 February 2018

volume

39

1 reference

4 February 2018

issue

2 Pt 1

1 reference

4 February 2018

page(s)

220-225

1 reference

4 February 2018

Extracorporeal photochemotherapy in systemic sclerosis and severe morphea

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970079-9

7 January 2021

Low-dose cyclosporine A in the treatment of disabling morphea

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970079-9

7 January 2021

Treatment of severe forms of localized scleroderma with oral corticosteroids: follow-up study on 17 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970079-9

7 January 2021

Successful treatment of scleroderma with PUVA therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970079-9

7 January 2021

Treatment of localised scleroderma with PUVA bath photochemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970079-9

7 January 2021

Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970079-9

7 January 2021

Use of a durometer to assess skin hardness

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970079-9

7 January 2021

Reliability of two methods to assess morphea: skin scoring and the use of a durometer.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970079-9

7 January 2021

Prediction of creatinine clearance from serum creatinine

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970079-9

7 January 2021

The pharmacology and clinical use of methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970079-9

7 January 2021

Effects of methotrexate on glycosaminoglycan production by scleroderma fibroblasts in culture

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970079-9

7 January 2021

Methotrexate: mechanism of action in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970079-9

7 January 2021

Demonstration of interleukin-2, interleukin-4 and interleukin-6 in sera from patients with localized scleroderma

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970079-9

7 January 2021

Demonstration of interleukin 8 in serum samples of patients with localized scleroderma

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970079-9

7 January 2021

Effect of methotrexate alone or in combination with sulphasalazine on the production and circulating concentrations of cytokines and their antagonists. Longitudinal evaluation in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970079-9

7 January 2021

Increased spontaneous production of IL-8 in peripheral blood monocytes from the psoriatic patient: relation to focal infection and response to treatments

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970079-9

7 January 2021

Methotrexate action in rheumatoid arthritis: stimulation of cytokine inhibitor and inhibition of chemokine production by peripheral blood mononuclear cells

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970079-9

7 January 2021

Type III collagen aminopropeptide levels in serum of patients with progressive systemic scleroderma

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970079-9

7 January 2021

Serum type III procollagen aminopeptide for assessing liver damage in methotrexate-treated psoriatic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970079-9

7 January 2021

Treatment of systemic sclerosis with gamma-interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2898%2970079-9

7 January 2021

10.1016/S0190-9622(98)70079-9

Identifiers

DOI

1 reference

4 February 2018

1 reference

4 February 2018